# Proact: A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease

Study · id `cardio:ct-nct05099770` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05099770](<https://clinicaltrials.gov/study/NCT05099770>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05099770

Browse, organ or system: Kidneys; Metabolism  
Browse, condition area: Diabetes and metabolic disease; Kidney connections  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 685 participants.

## Technical summary

Registry record NCT05099770. Randomized; triple masking; primary purpose treatment. Start 2022-01-05 (actual); primary completion 2029-12 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 685 participants (planned count; ClinicalTrials.gov record NCT05099770, source copy `cardio:ctgov-nct05099770-2026-08-11`, retrieved 2026-10-26)
- Started: 2022-01-05 (actual) (ClinicalTrials.gov record NCT05099770, source copy `cardio:ctgov-nct05099770-2026-08-11`, retrieved 2026-10-26)
- Primary completion: 2029-12 (anticipated) (ClinicalTrials.gov record NCT05099770, source copy `cardio:ctgov-nct05099770-2026-08-11`, retrieved 2026-10-26)
- Completion: 2029-12 (anticipated) (ClinicalTrials.gov record NCT05099770, source copy `cardio:ctgov-nct05099770-2026-08-11`, retrieved 2026-10-26)
- Countries: United States; Mexico; Puerto Rico; Taiwan (ClinicalTrials.gov record NCT05099770, source copy `cardio:ctgov-nct05099770-2026-08-11`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05099770-2026-08-11`, retrieved 2026-10-26)

## The registry's words

- Brief title: Proact: A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease
- Condition: Type 2 Diabetes Mellitus
- Condition: Chronic Kidney Diseases
- Intervention (Biological): Renal Autologous Cell Therapy (REACT/ rilparencel)
- Intervention (Procedure): Sham Comparator
- Lead sponsor: Prokidney
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)

## Provenance

Content hash: c9d69f667e90446ba1a11c0119270fc6b3dce0f2e3602fad79fc9d4b5a0911e9
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
